title: Conditional Cytotoxic Anti-HIV Gene Therapy for Selectable Cell Modification.
abstract: Gene therapy remains one of the potential strategies to achieve a cure for HIV infection. One of the major limitations of anti-HIV gene therapy concerns recovering an adequate number of modified cells to generate an HIV-proof immune system. Our study addresses this issue by developing a methodology that can mark conditional vector-transformed cells for selection and subsequently target HIV-infected cells for elimination by treatment with ganciclovir (GCV). We used the herpes simplex virus thymidine kinase (TK) mutant SR39, which is highly potent at killing cells at low GCV concentrations. This gene was cloned into a conditional HIV vector, pNL-GFPRRESA, which expresses the gene of interest as well as green fluorescent protein (GFP) in the presence of HIV Tat protein. We show here that TK-SR39 was more potent that wild-type TK (TK-WT) at eliminating infected cells at lower concentrations of GCV. As the vector expresses GFP in the presence of Tat, transient expression of Tat either by Tat RNA transfection or transduction by a nonintegrating lentiviral (NIL) vector marked the cells with GFP for selection. In cells selected by this strategy, TK-SR39 was more potent at limiting virus replication than TK-WT. Finally, in Jurkat cells modified and selected by this approach, infection with CXCR4-tropic Lai virus could be suppressed by treatment with GCV. GCV treatment limited the number of HIV-infected cells, virus production, as well as virus-induced cytopathic effects in this model. We provide proof of principle that TK-SR39 in a conditional HIV vector can provide a safe and effective anti-HIV strategy.
authors.affiliation: Department of Biomedical Sciences, Texas Tech University Health Sciences Center , El Paso, Texas.
authors.forename: Himanshu
authors.initials: H
authors.lastname: Garg
authors.affiliation: Department of Biomedical Sciences, Texas Tech University Health Sciences Center , El Paso, Texas.
authors.forename: Anjali
authors.initials: A
authors.lastname: Joshi
mesh_terms: D002460:Cell Line; D002470:Cell Survival / Q000187:drug effects / Q000235:genetics; D004305:Dose-Response Relationship, Drug; D015774:Ganciclovir / Q000494:pharmacology; D015870:Gene Expression; D023061:Gene Order; D017930:Genes, Reporter; D041722:Genes, Transgenic, Suicide; D005814:Genes, Viral; D015316:Genetic Therapy; D005822:Genetic Vectors / Q000235:genetics; D015658:HIV Infections / Q000235:genetics* / Q000276:immunology / Q000628:therapy*; D006801:Humans; D016086:Lentivirus / Q000235:genetics; D009154:Mutation; D013937:Thymidine Kinase / Q000235:genetics / Q000378:metabolism; D014161:Transduction, Genetic; D014779:Virus Replication / Q000187:drug effects; D054322:tat Gene Products, Human Immunodeficiency Virus / Q000235:genetics / Q000378:metabolism
chemical_list: D054322:tat Gene Products, Human Immunodeficiency Virus; D013937:Thymidine Kinase; D015774:Ganciclovir